Ranbaxy receives final approval for simvastatin in Canada
This article was originally published in Scrip
Ranbaxy Laboratories has received final approval from Health Canada's Therapeutic Products Directorate to manufacture and market the lipid metabolism regulator, Ran-Simvastatin 5mg, 10mg, 20mg, 40mg and 80mg tablets (simvastatin), there. The company expects to launch Ran-Simvastatin in September at an affordable price that would benefit the Canadian healthcare system and patients. The generic market for simvastatin tablets in Canada is estimated at Cdn$153 million ($138.2 million).